#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Prolymphocytic leukaemia Non-Hodgkin's lymphoma unspecified histology indolent Chorioretinitis Angiosarcoma non-metastatic Neurodevelopmental disorder Non-small cell lung cancer Carcinoid tumour Pouchitis Acute graft versus host disease in liver Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Amyotrophic lateral sclerosis gene carrier Ichthyosis Cholestatic pruritus Oropharyngeal cancer recurrent VEXAS syndrome More trials…

    Learn about Rare Diseases

    Advanced systemic mastocytosis – Trials in Disease Progressive multifocal leukoencephalopathy Alternating hemiplegia of childhood Primary immunodeficiency syndrome – Trials in Disease Noonan syndrome Idiopathic inflammatory myopathy Glycogen storage disease type I – Basic Information Nephrotic syndrome – Trials in Disease Castleman’s disease – Life with Disease Haemophilia B with anti factor IX More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Phenylalanine Mps-216 Indocyanine Green ARI0008 Nizatidine Df6002 Follitropin Delta Bepranemab Int-787 Ttf-Ngr Iph5201 Dcc-3116 Mirtazapine Emibetuzumab EGANELISIB Pritelivir Ezabenlimab Siplizumab Cetuximab For-6219 More therapies…

    Learn about Your Condition

    Immunodeficiency congenital Migraine without aura Hepatitis alcoholic Postpartum haemorrhage Hyperlipidaemia C3 glomerulopathy Cachexia Adenovirus infection Latent tuberculosis Athetosis Neutropenia Brain stem glioma Biliary cancer metastatic Insomnia Von Hippel-Lindau disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Renal cell carcinoma

  • Study of Nivolumab and Ipilimumab for Patients with Advanced Kidney Cancer and Intermediate or Poor Risk Factors

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Austria Czechia France Greece Italy Poland +2

  • Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Incb099280
    • Ipilimumab
    Norway Slovakia Sweden

  • Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Bladder cancer
    • Gastric cancer
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Austria Denmark Finland France Germany Italy +3

  • Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Italy Poland Spain

  • Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Belzutifan
    • Cabozantinib
    • Lenvatinib
    Austria Belgium Czechia Finland France Germany +7

  • Study of Axitinib and Immune Checkpoint Inhibitors for Patients with Untreated Advanced or Metastatic Kidney Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    • Renal cell carcinoma
    France Germany Poland Spain
Previous Page
1 … 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!